

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT BY
APPLICANT**
(Use as many sheets as necessary)

Sheet	1	of	9	Docket Number	079259-0237
-------	---	----	---	---------------	-------------

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
	AZ5	Fedyk, et al., "Regional Immunomodulation of the gastrointestinal tract without systemic Immunosuppression in Cynomolgus macaques by vedolizumab," 15(S2): S50, Abstract P-0144, <i>Inflammatory Bowel Diseases</i> , (2009).	
	AR6	Feagan, et al., "Emerging Safety Profile of Vedolizumab: A novel, selective Integrin Inhibitor for the treatment of IBD," 15(S2): S12, Abstract P-0025, <i>Inflammatory Bowel Diseases</i> , (2009).	
EXAMINER		DATE CONSIDERED	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.